metformin has been researched along with dapagliflozin in 149 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (2.01) | 29.6817 |
| 2010's | 94 (63.09) | 24.3611 |
| 2020's | 52 (34.90) | 2.80 |
| Authors | Studies |
|---|---|
| Washburn, WN | 1 |
| Fiedorek, FT; List, JF; Morales, E; Tang, W; Woo, V | 1 |
| Calado, J | 1 |
| Bailey, CJ; Bastien, A; Gross, JL; List, JF; Pieters, A | 1 |
| Boulton, DW; Griffen, SC; Kasichayanula, S; LaCreta, FP; Li, T; Liu, X; Pfister, M; Shyu, WC; Zhang, W | 1 |
| Del Prato, S; Durán-García, S; Elze, M; Meier, JJ; Nauck, MA; Parikh, SJ; Rohwedder, K | 1 |
| Bolinder, J; Johansson, L; Kullberg, J; Langkilde, AM; Ljunggren, Ö; Parikh, S; Sugg, J; Wilding, J | 1 |
| Hennicken, D; Henry, RR; List, JF; Marmolejo, MH; Murray, AV; Ptaszynska, A | 1 |
| Bolinder, J; Johansson, L; Langkilde, AM; Ljunggren, Ö; Parikh, S; Sjöström, CD; Sugg, J; Wilding, J | 2 |
| Plosker, GL | 1 |
| Bailey, CJ; Gross, JL; Hennicken, D; Iqbal, N; List, JF; Mansfield, TA | 1 |
| Pahor, A; Parikh, S; Rohwedder, K; Soler, NG; Sugg, J; Wilding, JP; Woo, V | 1 |
| Del Prato, S; Nauck, M | 1 |
| del Prato, S; Durán-García, S; Elze, M; Meier, JJ; Nauck, M; Parikh, SJ; Rohwedder, K | 1 |
| Parikh, S; Rohwedder, K; Sugg, J; Wilding, JP; Woo, V | 1 |
| Bilo, HJ; Drion, I; Goudswaard, AN; Holleman, F; Kleefstra, N; van Hateren, KJ | 1 |
| Hardy, E; Jabbour, SA; Parikh, S; Sugg, J | 1 |
| Boden, G; Chalamandaris, AG; Duchesne, D; Henry, RR; Iqbal, N; List, J; Mudaliar, S; Smith, S | 1 |
| Barnett, AH; Goring, S; Hawkins, N; Roudaut, M; Townsend, R; Wood, I; Wygant, G | 1 |
| Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J | 1 |
| Grandy, S; Hashemi, M; Langkilde, AM; Parikh, S; Sjöström, CD | 1 |
| Abdul-Ghani, MA; Daniele, G; DeFronzo, RA; Eldor, R; Fiorentino, TV; Merovci, A; Norton, L; Perez, Z; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Grandy, S; Langkilde, AM; Parikh, S; Sjöström, CD; Sugg, JE | 1 |
| Bergenheim, K; Ekman, M; Granström, O; McEwan, P; Sabale, U | 1 |
| Del Prato, S; Durán-García, S; Langkilde, AM; Nauck, MA; Parikh, SJ; Rohwedder, K; Sugg, J | 1 |
| Dou, J; Lu, J; Zhang, Q | 1 |
| Apanovitch, AM; de Bruin, TW; Johnsson, KM; List, JF; Parikh, SJ; Ptaszynska, A | 1 |
| Burgess, L; de Bruin, TW; Hamer-Maansson, JE; Hruba, V; Korányi, L; Schumm-Draeger, PM | 1 |
| Bennett, H; Bergenheim, K; McEwan, P; Ward, T | 1 |
| Cook, W; Hansen, L; Hirshberg, B; Iqbal, N; Li, Y; Rosenstock, J; Zee, P | 1 |
| Bailey, CJ; List, JF; Morales Villegas, EC; Ptaszynska, A; Tang, W; Woo, V | 1 |
| Bowering, K; Grohl, A; Matthaei, S; Parikh, S; Rohwedder, K | 1 |
| Abdul-Ghani, M | 1 |
| Del Prato, S; Durán-Garcia, S; Maffei, L; Nauck, M; Parikh, S; Rohwedder, K; Theuerkauf, A | 1 |
| Rupprecht, H | 1 |
| Bergenheim, K; Callan, L; Charokopou, M; Lister, S; McEwan, P; Postema, R; Roudaut, M; Tolley, K; Townsend, R | 2 |
| Boulton, DW; Chang, M; Cui, D; Griffen, SC; LaCreta, F; Liang, D; Liu, X; Lubin, S; Quamina-Edghill, D | 1 |
| Bowering, K; Johnsson, E; Matthaei, S; Parikh, S; Rohwedder, K; Sugg, J | 1 |
| Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Li, D; Mathieu, C; Ranetti, AE | 1 |
| Catrinoiu, D; Celiński, A; Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Matthaei, S | 1 |
| Grandy, S; Rohwedder, K; Ryden, A; Sternhufvud, C; Sugg, J | 1 |
| Hu, J; Tan, X | 1 |
| Yacoub, T | 1 |
| Han, P; Iqbal, N; Johnsson, E; Mansfield, T; Min, KW; Ptaszynska, A; T'Joen, C; Wang, B; Yang, W | 1 |
| Boulton, DW; Chang, M; Griffen, SC; Kitaura, C; LaCreta, F; Lubin, S; Pollack, A | 1 |
| Kamaruddin, NA; Kori, N; Mohd Noor, N; Mustafa, N; Othman, H; Rajoo, S; Sukor, N; Wahab, NA; Wan Seman, WJ | 1 |
| Shyangdan, DS; Uthman, OA; Waugh, N | 1 |
| Geissel, W | 1 |
| Hemmingsen, B; Krogh, J; Metzendorf, MI; Richter, B | 1 |
| de Bruin, TW; Hamer-Maansson, JE; Parikh, S; Reele, S; Tang, W | 1 |
| Edelsberger, T | 1 |
| Valek, R; Von der Mark, J | 1 |
| Kourlaba, G; Maniadakis, N; Tentolouris, N; Tzanetakos, C | 1 |
| Abiru, N; Ando, T; Horie, I; Kawakami, A; Shigeno, R | 1 |
| Naito, T; Okamoto, A; Sanada, H; Yokokawa, H | 1 |
| Chen, H; Garcia-Sanchez, R; González González, JG; Hansen, L; Herrera Marmolejo, M; Iqbal, N; Johnsson, E; Mathieu, C | 1 |
| Aggarwal, N; Chen, H; Chin, A; Garcia-Hernandez, P; Hansen, L; Iqbal, N; Johnsson, E; Matthaei, S | 1 |
| Bloch, MJ | 1 |
| Wise, J | 1 |
| Carlsson, B; Chen, H; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Johnsson, E | 1 |
| Buchholt, AT; El Khoury, AC; Kamal, A; Schubert, A; Taieb, V | 1 |
| Lingvay, I | 1 |
| Amadid, H; Færch, K; Jørgensen, ME; Karstoft, K; Nielsen, LB; Persson, F; Ried-Larsen, M | 1 |
| Drexler, A | 1 |
| Aronson, R; Brown, RE; Gupta, N | 1 |
| Coppenrath, VA; Hydery, T | 1 |
| Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Öhman, P | 1 |
| Bhatt, DL; Bonaca, MP; Cahn, A; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD | 1 |
| Bell, KF; Chakravarty, A; Dhankhar, P; Rastogi, M | 1 |
| Chen, H; Del Prato, S; Garcia-Sanchez, R; Hansen, L; Iqbal, N; Johnsson, E; Mathieu, C; Rosenstock, J | 1 |
| Albiero, M; Avogaro, A; Bonora, BM; Bortolozzi, M; Cappellari, R; Ceolotto, G; Fadini, GP; Menegazzo, L; Romanato, F; Scattolini, V; Vigili de Kreutzeberg, S | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Chatsudthipong, V; Chattipakorn, N; Chueakula, N; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Thongnak, L; Wanchai, K | 1 |
| Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, S; Öhman, P; Wang, H | 1 |
| Bell, KF; Eudicone, JM; Gani, R; Huang, H; Krukas-Hampel, MR; Tugwell, CW | 1 |
| Aiello, V; Brancato, D; Di Noto, A; Fleres, M; Provenzano, F; Provenzano, V; Saura, G; Scorsone, A; Spano, L | 1 |
| Csomós, K; Cypryk, K; Dronamraju, N; Garcia-Sanchez, R; Jacob, S; Johnsson, E; Kellerer, M; Kurlyandskaya, R; Müller-Wieland, D; Rohwedder, K; Seufert, J; Sjöström, CD; Skripova, D | 1 |
| Frias, JP; McPheeters, JT; Parker, ED; Wittbrodt, ET | 1 |
| Henry, RR; Katz, A; Klein, D; Mansfield, T; Pettus, J; Shi, L; Strange, P; Zhou, R; Zhuplatov, SB | 1 |
| Cho, HC; Kim, NH; Kim, SG; Kwak, SH; Lee, J; Lee, YH; Lim, S; Moon, JS; Moon, MK | 1 |
| Chen, H; Garcia-Sanchez, R; Mathieu, C; Rosenstock, J; Saraiva, GL | 1 |
| Del Prato, S; Garcia-Sanchez, R; Handelsman, Y; Iqbal, N; Johnsson, E; Kurlyandskaya, R; Mathieu, C; Rosenstock, J | 1 |
| Åkerblom, A; Johansson, L; Karlsson, C; Latva-Rasku, A; Lisovskaja, V; Nuutila, P; Oldgren, J; Oscarsson, J | 1 |
| Donnan, K; Segar, L | 1 |
| Asseburg, C; Neslusan, C; Willis, M | 1 |
| Cai, X; Chen, Y; Gu, S; Ji, L; Nie, L; Shi, L; Yang, W | 1 |
| Chin, KL; Hird, TR; Liew, D; Magliano, DJ; Ofori-Asenso, R; Si, S; Zoungas, S | 1 |
| García-Sánchez, R; Jacob, S; Johnsson, E; Perl, S; Rosenstock, J | 1 |
| Barakat, GH; Elkady, EF; Hassib, ST; Taha, EA | 1 |
| Boulton, DW; Dayton, B; Engman, H; Tang, W; Zhu, Y | 1 |
| Bhutani, R; Bodla, RB; Kant, R; Kapoor, G | 1 |
| Druyts, E; Kanters, S; Lopes, S; Popoff, E; Sharma, R; Vrazic, H; Wilkinson, L | 1 |
| Shah, PA; Sharma, V; Shrivastav, PS; Yadav, MS | 1 |
| Bae, JC; Hwang, YC; Kim, HJ; Kim, JH; Kim, SY; Kwak, SH; Lee, EY; Lee, S; Suh, S; Won, JC | 1 |
| Bai, XY; Sun, Q; Tang, Y; Zhang, M; Zhou, QL; Zhou, YF | 1 |
| Chatsudthipong, V; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Swe, MT; Thongnak, L | 2 |
| Bozovic, A; Danser, AHJ; Emanuel, AL; Geurts, F; Hoorn, EJ; Joles, JA; Kramer, MHH; Larsen, EL; Muskiet, MHA; Nieuwdorp, M; Poulsen, HE; Smits, MM; Tonneijck, L; Touw, DJ; van Baar, MJB; van Bommel, EJM; van Raalte, DH | 1 |
| Bjornstad, P; Nelson, RG; Pavkov, ME | 1 |
| Dronamraju, N; Ekholm, E; Garcia-Sanchez, R; Jabbour, SA; Johnsson, E; Lind, M; Vilsbøll, T | 1 |
| Dronamraju, N; Frias, JP; Garcia-Sanchez, R; Gonzalez-Galvez, G; Johnsson, E; Maaske, J; Peters, AL; Simonson, DC; Testa, MA | 1 |
| Espinosa, E; Ferreira-Hermosillo, A; Garrido-Mendoza, AP; Mendoza-Zubieta, V; Mercado, M; Molina-Ayala, MA; Molina-Guerrero, D; Ramírez-Rentería, C | 1 |
| Dronamraju, N; Garcia-Sanchez, R; Hockings, PD; Johansson, L; Johnsson, E; Maaske, J; Wilding, JPH | 1 |
| Fernandez-Fernandez, B; Ortiz, A; Porrini, E; Soler, MJ | 1 |
| van Bommel, EJM; van Raalte, DH | 1 |
| Cui, L; Hao, Z; Li, G; Sun, Y; Yan, D | 1 |
| Anwar, MM; Awad, M; Carapinha, JL; Elebrashy, I; Elhadad, H; Elsisi, GH; Khattab, M; Wafa, A | 1 |
| Aronson, R; Gerstein, HC; Hall, S; Harris, S; Hramiak, I; Liu, YY; McInnes, N; Sigal, RJ; Sultan, F; Woo, V | 1 |
| Ahn, DJ; Lee, IH | 1 |
| El-Domiaty, H; El-Nabi, SH; Fayez Ewida, S; Hanna, G; Saleh, S; Shabaan, A | 1 |
| Bobade, PS; Dhote, AM; Ganorkar, SB; Patil, MR; Sharma, SS; Shirkhedkar, AA | 1 |
| Rasouli, N | 1 |
| Deng, X; Hu, S; Li, Z; Ma, Y; Wang, Y | 1 |
| Li, M; Song, J; Ying, M; Zhuang, Y | 1 |
| Ahmed, A; Choi, J; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Sjöström, CD | 1 |
| Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Dejgaard, TF; Færch, K; Jørgensen, ME; Karstoft, K; Pedersen, C; Persson, F; Ried-Larsen, M; Tvermosegaard, M; Vainø, CTR; Vistisen, D | 1 |
| Bengtsson, O; DeMets, DL; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Sabatine, MS; Sjöstrand, M; Solomon, SD | 1 |
| Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Faerch, K; Holst, JJ; Jørgensen, ME; Karstoft, K; Persson, F; Quist, JS; Ried-Larsen, M; Torekov, SS; Vistisen, D; Wewer Albrechtsen, NJ | 1 |
| Kurozumi, A; Okada, Y; Tanaka, Y | 1 |
| Elkind-Hirsch, KE; Harris, R; Seidemann, E | 1 |
| Bastian, M; Brath, H; Harreiter, J; Just, I; Kautzky-Willer, A; Klepochova, R; Krššák, M; Leutner, M; Schelkshorn, C | 1 |
| Bairaktari, E; Bletsa, E; Chasapi, S; Dafopoulos, P; Dimou, A; Ferrannini, E; Filippas-Dekouan, S; Kostara, C; Koutsovasilis, A; Pappa, E; Spyroulias, G; Tsimihodimos, V | 1 |
| Barreto, J; Bonilha, I; Breder, I; Breder, JC; Carvalho, LSF; Cavalcante, P; Cintra, RMR; de Lima-Junior, JC; do Carmo, HRP; Kimura-Medorima, ST; Moreira, C; Moura, FA; Munhoz, DB; Nadruz, W; Oliveira, DC; Quinaglia, T; Soares, AAS; Sposito, AC | 1 |
| Bellanger, D; Chappell, N; Elkind-Hirsch, KE; Seidemann, E; Storment, J | 1 |
| Barreto, J; Breder, I; Cintra, RM; de Carvalho, LSF; Guerra-Júnior, G; Kimura-Medorima, ST; Munhoz, DB; Muscelli, E; Nadruz, W; Quinaglia, T; Soares, AAS; Sposito, AC; Wolf, VLW | 1 |
| Frías, JP; Hockings, PD; Iqbal, N; Johansson, L; Maaske, J; Suchower, L; Wilding, JPH | 1 |
| Cheng, L; Fan, Y; Fu, Q; Lin, W; Liu, F; Wu, X; Zhang, X; Zhou, L | 1 |
| Fan, X; Guo, F; Huang, F; Liu, Y; Qin, G; Song, Y; Zhao, L | 1 |
| García, Á; Gil-Rojas, Y; Lasalvia, P | 1 |
| Bi, Y; Cheng, H; Liu, J; Miao, Y; Ni, W; Wang, J; Zhang, B; Zhang, W; Zhang, Z | 1 |
| Alegete, P; Boodida, S; Vankalapati, KR | 1 |
| Huh, Y; Kim, YS | 1 |
| Abdallah, DM; Ahmed, KA; El-Abhar, HS; Fleifel, AM; Soubh, AA | 1 |
| Ahn, SH; Cho, Y; Choi, YJ; Hong, S; Kim, SH; Lee, E; Lee, YH; Seo, DH; Seo, S; Suh, YJ | 1 |
| Aly, RG; Alzaim, I; El-Mallah, A; El-Yazbi, AF; Shaaban, HH; Wahid, A | 1 |
| Alyafei, S; Awaisu, A; Elewa, H; Mahfouz, A; Zaghloul, N | 1 |
| Abhari, AP; Fakhrolmobasheri, M; Heidarpour, M; Manshaee, B; Mazaheri-Tehrani, S; Mohammadbeigi, E; Mozafari, AM; Shafie, D | 1 |
| Cho, SA; Cho, SI; Chon, S; Han, KA; Hong, EG; Jeong, IK; Kim, DM; Kim, YH; Lee, BW; Nah, JJ; Sohn, TS; Son, JW; Song, HR; Yoon, KH | 1 |
| Ahmed, AZ; Ashwal, AJ; Bairy, LK; Bharati, S; Sainath, P; Satyam, SM; Shetty, P; Singh, VK | 1 |
| Cho, JH; Han, JM; Han, JY; Han, KA; Kang, ES; Kang, JG; Kim, CS; Kim, KS; Kim, MK; Kim, NH; Kim, S; Kim, SH; Kim, SS; Kim, SY; Kim, TH; Kim, TN; Kim, YH; Koh, G; Lee, JH; Lee, KY; Lee, SE; Lim, S; Mok, JO; Nah, JJ; Park, CY; Park, JH; Song, HR; Song, KH; Won, KC | 1 |
| Gu, R; Hao, H; Jia, J; Kang, L; Li, Z; Qi, Y; Qiao, S; Sun, X; Wang, K; Xu, B; Zhang, Q; Zhang, X | 1 |
| Arya, VV; Giri, R; Gofne, SK; Gupta, SK; Joglekar, SJ; Karnawat, SR; Kumar, SR; Kurmi, P; Lakhwani, LK; Mehta, SC; Mishra, A; Mohan, B; Murthy, LS; Patel, PM; Rajurkar, MN; Sahay, RK; Sawardekar, VM; Shembalkar, JV; Sonawane, AR; Soni, PN | 1 |
| Chon, S; Hong, EG; Kang, JG; Kim, JH; Kim, SY; Ku, BJ; Lee, BW; Lee, WY; Min, K; Park, MK; Song, K; Yoo, SJ | 1 |
| Boulton, DW; Hui, A; Ning, R; Tang, W; Zhao, X | 1 |
| Hong, JH; Lim, S; Moon, JS; Seong, K | 1 |
| Chung, CH; Han, KA; Hong, EG; Kim, DJ; Kim, ES; Kim, HJ; Koh, GP; Lee, CB; Moon, JS; Park, CY; Park, IR; Won, JC; Won, KC; Yoon, KH; Yu, JM | 1 |
| Htun, KT; Jaikumkao, K; Kothan, S; Lungkaphin, A; Montha, N; Pengrattanachot, N; Phengpol, N; Promsan, S; Sriburee, S; Sutthasupha, P; Thongnak, L | 1 |
23 review(s) available for metformin and dapagliflozin
| Article | Year |
|---|---|
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Administration, Oral; Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glipizide; Glucosides; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transport Proteins; Treatment Outcome | 2012 |
[SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin].
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Netherlands; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2013 |
Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2014 |
Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Topics: Benzhydryl Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged | 2014 |
[The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Combination therapy for type 2 diabetes: dapagliflozin plus metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Dapagliflozin combination therapy in type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Metformin; Treatment Outcome | 2016 |
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Topics: Bayes Theorem; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Weight Loss | 2016 |
Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fasting; Glucose Intolerance; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Topics: Bayes Theorem; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; United Arab Emirates | 2017 |
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil | 2017 |
Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Tablets | 2018 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes.
Topics: Acidosis, Lactic; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Metformin; Risk; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
Topics: Administration, Oral; Age Factors; Age of Onset; Benzhydryl Compounds; Body Weight; China; Cholesterol; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Expenditures; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Severity of Illness Index; Sex Factors; Socioeconomic Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Pharmaceutical Analytical Profile for Novel SGL-2 Inhibitor: Dapagliflozin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of sodium-glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
77 trial(s) available for metformin and dapagliflozin
| Article | Year |
|---|---|
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Sodium-Glucose Transport Proteins; Weight Loss; Young Adult | 2009 |
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2010 |
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult | 2011 |
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Glipizide; Glucosides; Humans; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2011 |
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Topics: Adipose Tissue; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome | 2012 |
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult | 2012 |
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.
Topics: Absorptiometry, Photon; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Osteogenesis; Osteoporosis; Time Factors; Treatment Outcome | 2012 |
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Placebos; Treatment Outcome | 2013 |
[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Long-Term Care; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Topics: Aged; Balanitis; Benzhydryl Compounds; Blood Glucose; Body Weight; Candidiasis, Vulvovaginal; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glipizide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2013 |
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss | 2014 |
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Health Status; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Risk Assessment; Surveys and Questionnaires; Treatment Outcome; Weight Loss | 2014 |
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucose; Glucose Clamp Technique; Glucosides; Humans; Hyperglycemia; Insulin; Male; Metformin; Middle Aged; Muscles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors | 2014 |
Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Health Status; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Time Factors | 2014 |
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2014 |
Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
Topics: Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Europe; Feasibility Studies; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Membrane Transport Modulators; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; South Africa | 2015 |
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2015 |
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Urinary Tract Infections | 2015 |
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Health Care Costs; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Overweight; Quality-Adjusted Life Years; Risk; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; United Kingdom; Weight Loss | 2015 |
Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
Topics: Adult; Benzhydryl Compounds; Chemistry, Pharmaceutical; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Fasting; Female; Food-Drug Interactions; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult | 2015 |
Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Urinary Tract Infections | 2015 |
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2015 |
Patient-reported outcomes among patients with type 2 diabetes mellitus treated with dapagliflozin in a triple-therapy regimen for 52 weeks.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diagnostic Self Evaluation; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Outcome Assessment; Patient Satisfaction; Quality of Life; Sulfonylurea Compounds; Surveys and Questionnaires; Treatment Outcome | 2016 |
Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos | 2016 |
Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
Topics: Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Brazil; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Fasting; Female; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult | 2016 |
Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Fasting; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Young Adult | 2016 |
[New attempt in a benefit evaluation].
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Metformin; Sulfonylurea Compounds | 2015 |
Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability.
Topics: Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Biological Availability; Cross-Over Studies; Drug Combinations; Fasting; Female; Food-Drug Interactions; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult | 2016 |
Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2016 |
One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
Topics: Adamantane; Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Prediabetic State; Research Design; Risk Factors | 2017 |
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
Topics: Anti-Obesity Agents; Benzhydryl Compounds; Blood Pressure; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2018 |
DECLARE-TIMI 58: Participants' baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Obesity; Prevalence; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo.
Topics: Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Extracellular Traps; Female; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Neutrophils | 2018 |
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Middle Aged; Sodium-Glucose Transport Proteins | 2018 |
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Urinary Tract Infections | 2018 |
Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Postprandial Period; Treatment Outcome; Young Adult | 2018 |
Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial.
Topics: Adamantane; Adult; Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Drug Monitoring; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Treatment Outcome | 2018 |
Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2019 |
Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients-a description of the DAPACARD study.
Topics: Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart; Heart Ventricles; Hospitalization; Humans; International Cooperation; Magnetic Resonance Imaging; Metformin; Myocardial Contraction; Nuclear Medicine; Outcome Assessment, Health Care; Perfusion; Positron-Emission Tomography; Risk; Sample Size; Sodium-Glucose Transporter 2 | 2019 |
Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2019 |
Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects.
Topics: Adamantane; Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Delayed-Action Preparations; Dipeptides; Drug Combinations; Female; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult | 2019 |
Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Fasting; Female; Glucosides; Glycemic Control; Humans; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Young Adult | 2020 |
Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sleep; Sleep Apnea, Obstructive; Treatment Outcome | 2019 |
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Gliclazide; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Kidney; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Vasoconstriction; Vasodilation | 2020 |
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Treatment Outcome | 2020 |
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2020 |
Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Mexico; Middle Aged; Obesity, Morbid; Prediabetic State; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Waist Circumference; Weight Loss; Young Adult | 2020 |
Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes.
Topics: Adamantane; Adipose Tissue; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Humans; Liver; Metformin | 2020 |
Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exercise; Female; Glucosides; Glycated Hemoglobin; Healthy Lifestyle; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Recurrence; Remission Induction; Secondary Prevention; Time Factors; Treatment Outcome | 2020 |
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult | 2020 |
The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Denmark; Exercise; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Overweight; Prediabetic State; Treatment Outcome | 2021 |
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Proportional Hazards Models; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome | 2020 |
No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prediabetic State | 2021 |
A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucosides; Humans; Hypoglycemic Agents; Metformin; Overweight; Pregnancy; Prospective Studies; Single-Blind Method | 2020 |
Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-contr
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Lipids; Liver Neoplasms; Metformin; Middle Aged; Pilot Projects; Prospective Studies; Treatment Outcome; Young Adult | 2021 |
Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Greece; Humans; Male; Metabolome; Metformin; Middle Aged; Treatment Outcome; Urinalysis | 2021 |
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Brazil; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Glucosides; Glyburide; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vasodilation | 2021 |
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Drug Therapy, Combination; Exenatide; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Phentermine; Polycystic Ovary Syndrome; Prospective Studies; Single-Blind Method; Topiramate; Treatment Outcome; Weight Loss; Young Adult | 2021 |
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus.
Topics: Absorptiometry, Photon; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Composition; Body Weight; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glyburide; Glycated Hemoglobin; Hand Strength; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2021 |
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
Topics: Adamantane; Adipose Tissue; Adolescent; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Metformin; Sulfonylurea Compounds; Treatment Outcome | 2022 |
Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
Topics: Acarbose; Benzhydryl Compounds; Blood Glucose; Cognition; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin | 2022 |
Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2023 |
Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |
Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin | 2023 |
Pharmacokinetic Variables of Dapagliflozin/Metformin Extended-release Fixed-dose Combination in Healthy Chinese Volunteers and Regional Comparison.
Topics: Adult; Area Under Curve; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; East Asian People; Female; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Tablets; Therapeutic Equivalency | 2023 |
Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extensio
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin | 2023 |
49 other study(ies) available for metformin and dapagliflozin
| Article | Year |
|---|---|
[SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glipizide; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2013 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Kidney Failure, Chronic; Metformin; Microcirculation; Middle Aged; Myocardial Infarction; Nutrition Surveys; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Uric Acid | 2014 |
Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
Topics: Benzhydryl Compounds; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Models, Economic; Quality-Adjusted Life Years; Scandinavian and Nordic Countries; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2015 |
Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Models, Economic; Risk Factors; Sulfonylurea Compounds; United Kingdom | 2015 |
Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Female; Glucosides; Humans; Male; Metformin | 2015 |
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Sodium-Glucose Transport Proteins; State Medicine; United Kingdom | 2015 |
[XIGDUO - fixed combination of the active ingredients dapagliflozin and metformin].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transport Proteins | 2016 |
[Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
Topics: Benzhydryl Compounds; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucosides; Greece; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Antibodies; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2016 |
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.
Topics: Adipocytes; Adiponectin; Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; C-Reactive Protein; Creatinine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1 | 2016 |
Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
Topics: Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Blood Pressure Determination; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Metformin; Off-Label Use; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
NICE recommends new triple therapy option for type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Practice Guidelines as Topic; Sulfonylurea Compounds; United Kingdom | 2016 |
Can we go beyond surrogates?
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canada; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Registries; Retrospective Studies; Treatment Outcome | 2017 |
Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Health Expenditures; Health Resources; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years; Sulfonylurea Compounds; Thiazolidinediones; United Nations; United States | 2018 |
Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
Topics: Animals; Benzhydryl Compounds; Diet, High-Fat; Disease Models, Animal; Glucosides; Humans; Insulin; Insulin Resistance; Kidney; Kidney Diseases; Male; Metformin; Obesity; Organic Anion Transporters, Sodium-Independent; Oxidative Stress; Rats; Rats, Wistar; Signal Transduction; Sodium-Glucose Transporter 2 | 2018 |
A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Registries; Retrospective Studies; Treatment Outcome | 2018 |
Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Treatment Outcome | 2018 |
Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin.
Topics: Adult; Benzhydryl Compounds; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Health Resources; Humans; Insurance Claim Review; Male; Medicare Part D; Metformin; Middle Aged; Patient Acceptance of Health Care; Retrospective Studies; Sitagliptin Phosphate; United States | 2019 |
Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Metformin; Probability | 2019 |
Validated Liquid Chromatographic Method for the Determination of (Canagliflozin, Dapagliflozin or Empagliflozin) and Metformin in the Presence of (1-Cyanoguanidine).
Topics: Benzhydryl Compounds; Canagliflozin; Chromatography, High Pressure Liquid; Glucosides; Guanidines; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design.
Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Dose-Response Relationship, Drug; Gliclazide; Glucosides; Linagliptin; Metformin; Molecular Structure; Pioglitazone; Pyrazoles; Software; Structure-Activity Relationship; Thiazolidines | 2019 |
Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC-MS/MS.
Topics: Benzhydryl Compounds; Calibration; Canagliflozin; Chromatography, Liquid; Glucosides; Humans; Limit of Detection; Metformin; Plasma; Reproducibility of Results; Sodium-Glucose Transporter 2 Inhibitors; Solid Phase Extraction; Tandem Mass Spectrometry | 2019 |
Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diet, High-Fat; Endoplasmic Reticulum Stress; Gluconeogenesis; Glucosides; Glycosuria; Insulin Resistance; Liver; Male; Metformin; Obesity; Pancreas; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Hemodynamics; Humans; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vasoconstriction; Vasodilation; Young Adult | 2020 |
Dapagliflozin attenuates renal gluconeogenic enzyme expression in obese rats.
Topics: Animals; Benzhydryl Compounds; Diet, High-Fat; Gluconeogenesis; Glucose-6-Phosphatase; Glucosides; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Proteins; Intracellular Signaling Peptides and Proteins; Kidney; Male; Metformin; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Rats; Rats, Wistar | 2020 |
SGLT2i and postglomerular vasodilation.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Metformin; Sodium-Glucose Transporter 2; Vasoconstriction; Vasodilation | 2020 |
The authors reply.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Metformin; Sodium-Glucose Transporter 2; Vasoconstriction; Vasodilation | 2020 |
Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients.
Topics: Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2020 |
Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Topics: Benzhydryl Compounds; Budgets; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Egypt; Glucosides; Humans; Hypoglycemic Agents; Insulin; Metformin; Models, Economic; Renal Insufficiency; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2020 |
Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report.
Topics: Administration, Intravenous; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fluid Therapy; Glucosides; Humans; Hypernatremia; Hypoglycemic Agents; Hypokalemia; Insulin; Intestinal Pseudo-Obstruction; Kidney Pelvis; Metformin; Patient Discharge; Sodium-Glucose Transporter 2 Inhibitors; Ureter; Withholding Treatment | 2020 |
Dapagliflozin, a sodium glucose cotransporter 2 inhibitors, protects cardiovascular function in type-2 diabetic murine model.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Glucosides; Metformin; Random Allocation; Rats; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2020 |
An Escape From Diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Insulin Glargine; Metformin | 2020 |
Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus.
Topics: Adamantane; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Glucosides; Humans; Metformin; Prospective Studies; Randomized Controlled Trials as Topic | 2021 |
Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
Topics: Adult; Ambulatory Care; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome.
Topics: Adult; Benzhydryl Compounds; Body Weight; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin; Male; Metabolic Syndrome; Metformin; Middle Aged; Monocytes | 2021 |
Identification of circular RNAs and functional competing endogenous RNA networks in human proximal tubular epithelial cells treated with sodium-glucose cotransporter 2 inhibitor dapagliflozin in diabetic kidney disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetic Nephropathies; Epithelial Cells; Glucose; Glucosides; Humans; Hypoglycemic Agents; In Situ Hybridization, Fluorescence; Metformin; MicroRNAs; RNA, Circular; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2022 |
Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Colombia; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years | 2022 |
Stability-indicating HPLC method development and validation for simultaneous estimation of metformin, dapagliflozin, and saxagliptin in bulk drug and pharmaceutical dosage form.
Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Drug Stability; Glucosides; Metformin; Tablets | 2022 |
Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care.
Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Metformin; Primary Health Care; Weight Loss | 2022 |
Preferential effect of Montelukast on Dapagliflozin: Modulation of IRS-1/AKT/GLUT4 and ER stress response elements improves insulin sensitivity in soleus muscle of a type-2 diabetic rat model.
Topics: Acetates; Animals; Antioxidants; Benzhydryl Compounds; Blood Glucose; Cyclopropanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endoplasmic Reticulum; Endoribonucleases; Glucose Transporter Type 4; Glucosides; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Leukotriene Antagonists; Metformin; Muscle, Skeletal; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Rats; Response Elements; Streptozocin; Sulfides | 2022 |
Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrimidines; Republic of Korea; Thiazolidinediones; Treatment Outcome | 2022 |
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Biomarkers; Cholesterol; Cholic Acid; Diet, High-Fat; Fibrosis; Glucosides; Inflammation; Insulin Resistance; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rats | 2022 |
A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Metformin; Qatar; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones | 2022 |
Metformin and Dapagliflozin Attenuate Doxorubicin-Induced Acute Cardiotoxicity in Wistar Rats: An Electrocardiographic, Biochemical, and Histopathological Approach.
Topics: Animals; Antioxidants; Cardiotoxicity; Diabetes Mellitus, Type 2; Doxorubicin; Electrocardiography; Glucose; Metformin; Myocardium; Oxidative Stress; Rats; Rats, Wistar | 2023 |
Anti-Diabetic Drugs Inhibit Bulimia Induced Obesity.
Topics: Animals; Bulimia; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hypoglycemic Agents; Male; Metformin; Mice; Obesity; Weight Loss | 2023 |
Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2023 |
Dapagliflozin and metformin in combination ameliorates diabetic nephropathy by suppressing oxidative stress, inflammation, and apoptosis and activating autophagy in diabetic rats.
Topics: Animals; Apoptosis; Autophagy; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Inflammation; Metformin; Oxidative Stress; Rats | 2024 |